First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® R&D investments of 5 billion EUR, or 21 percent of net sales Net sales rise 10.5 percent (currency adjusted)
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D macaubusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from macaubusiness.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.